Medicus Pharma Develops Non-Surgical Skin Cancer Patch & Prostate Therapy Pipeline

For biotech investors and healthcare innovators, this New to The Street interview features Dr. Raza Bokhari, CEO of Medicus Pharma, discussing a novel microneedle patch therapy designed to treat basal cell skin cancer non-invasively by delivering targeted micro-doses of chemotherapy directly to the lesion, potentially avoiding surgery, scarring, and long wait times while reducing treatment costs and improving patient experience, with Phase 2 data expected soon and a potential commercial pathway within the next few years. The company is also advancing Tevarellix, a next-generation hormone therapy aimed at advanced prostate cancer and acute urinary retention that may offer cardiovascular benefits compared to existing treatments, alongside an AI-assisted drug-development strategy focused on acquiring promising Phase-2-ready therapies, proving efficacy, and partnering with large pharmaceutical companies for commercialization. #MedicusPharma #NewToTheStreet #Biotech #SkinCancer #BasalCellCarcinoma #ProstateCancer #DrugDevelopment #ClinicalTrials #MedicalInnovation #HealthcareTechnology #CancerResearch #PharmaStocks #Nasdaq #BiotechInvesting